Spectrum Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Spectrum Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count).

52 total trials 1 currently recruiting 28 completed early-phase tilt top decile by trial count

Spectrum Pharmaceuticals: 52 sponsored US clinical trials, 1 recruiting.

Spectrum Pharmaceuticals sponsors 52 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 28 completed. 16 of these trials are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Phosphate Binding Capacity, with 1 trials.

Top-decile sponsor footprint

Spectrum Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

28 of 51 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (54.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

52 total, page 1 of 2

RECRUITING Phase 2

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

NCT04570423
COMPLETED Phase 1

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

NCT04981704
COMPLETED Phase 1

Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects

NCT04436562
COMPLETED Phase 1

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

NCT04187898
TERMINATED Phase 2

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

NCT04172597
TERMINATED Phase 1

A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

NCT03804515
TERMINATED Phase 2

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

NCT03744715
TERMINATED Phase 1

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

NCT03429101
TERMINATED Phase 2

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NCT03318939
TERMINATED Phase 3

A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)

NCT03224182
COMPLETED Phase 1

Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

NCT03135951
COMPLETED Phase 3

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

NCT02953340
TERMINATED Phase 1

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

NCT02519270
COMPLETED Phase 2

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

NCT02659514
COMPLETED Phase 3

SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)

NCT02643420
TERMINATED Phase 3

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

NCT02563561
TERMINATED Phase 2

Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

NCT01741155
TERMINATED Phase 2

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

NCT01773785
COMPLETED Phase 2

Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

NCT01724866
TERMINATED Phase 3

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

NCT01662102
TERMINATED Phase 2

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

NCT01587144
TERMINATED Phase 3

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

NCT01510184
COMPLETED Phase 1

Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb

NCT01560884
TERMINATED Phase 3

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL

NCT01439347
TERMINATED Phase 3

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT01469221
TERMINATED Phase 2

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

NCT01549886
TERMINATED Phase 3

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

NCT01420679
TERMINATED Phase 3

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

NCT01410565
COMPLETED Phase 1

A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

NCT01317927
COMPLETED Phase 2

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

NCT01252693
COMPLETED Phase 2

Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

NCT00998946
COMPLETED Phase 2

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT00865969
TERMINATED Phase 2

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

NCT00743184
COMPLETED Phase 1

Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors

NCT00765973
COMPLETED Phase 1

Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

NCT00656786
COMPLETED Phase 1

A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma

NCT00613691
COMPLETED Phase 2

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

NCT00606502
COMPLETED Phase 2

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

NCT00506142
TERMINATED Phase 1

Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00558727
COMPLETED Phase 3

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

NCT00598806
COMPLETED Phase 2

Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia

NCT00495079
COMPLETED Phase 3

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)

NCT00461591
COMPLETED Phase 2

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

NCT00427219
TERMINATED Phase 3

Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)

NCT00384111
COMPLETED Phase 1

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00364676
TERMINATED Phase 3

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

NCT00322218
COMPLETED Phase 2

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00090090
TERMINATED Phase 1

Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness

NCT00088023
COMPLETED Phase 3

Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer

NCT00083304
COMPLETED Phase 1

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

NCT00052442
Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 16
Phase 2 20
Phase 3 16

Therapeutic Areas

Phosphate Binding Capacity 1
Benign Prostatic Hypertrophy 1
EGFR Inhibitor-associated Rash 1
Safety 1
Acute Lymphoblastic Leukemia (ALL) 1
Carcinoma 1
Solid Tumors 1
Peripheral T-Cell Lymphoma 1
Metastatic Cancer 1
Bladder Cancer 1

What is open in the Spectrum Pharmaceuticals pipeline

1 recruiting of 52 indexed (2% open); 28 completed (54%).

Phase mix: 16 late (III/IV) vs 36 early (I/II) (early-phase heavy).

Top condition: Phosphate Binding Capacity (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Spectrum Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 52 registered trials and 2% open enrollment, not the therapeutic-area sidebar.

Spectrum Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200250300 0%5%10%15% Total trials Recruiting share Spectrum PharmaceuticalsAlbany Medical CollegeBurzynski Research InstituteDr. Reddy's Laboratories LimitedPTC TherapeuticsSociété des Produits Nestlé (SPN)Sanofi Pasteur, a Sanofi CompanyCarelon ResearchAlcon Research
Spectrum Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Spectrum Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 52 trials (± recruiting share)

Sponsors near 2% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Spectrum Pharmaceuticals page

52 registered trials is a research-attention snapshot, not an endorsement of Spectrum Pharmaceuticals or any single study.

  • 1 of Spectrum Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Phosphate Binding Capacity is the condition Spectrum Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Phosphate Binding Capacity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Spectrum Pharmaceuticals pipeline card: 52 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.